GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Conduit Pharmaceuticals Inc (FRA:ZK7) » Definitions » Notes Receivable

Conduit Pharmaceuticals (FRA:ZK7) Notes Receivable : €0.00 Mil (As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Conduit Pharmaceuticals Notes Receivable?

Conduit Pharmaceuticals's Notes Receivable for the quarter that ended in Mar. 2025 was €0.00 Mil.


Conduit Pharmaceuticals Notes Receivable Historical Data

The historical data trend for Conduit Pharmaceuticals's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Conduit Pharmaceuticals Notes Receivable Chart

Conduit Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Notes Receivable
- - - -

Conduit Pharmaceuticals Quarterly Data
Dec21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Conduit Pharmaceuticals Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Conduit Pharmaceuticals Notes Receivable Related Terms

Thank you for viewing the detailed overview of Conduit Pharmaceuticals's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Conduit Pharmaceuticals Business Description

Traded in Other Exchanges
Address
4581 Tamiami Trail North, Suite 200, Naples, FL, USA, 34103
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Conduit Pharmaceuticals Headlines

No Headlines